350 related articles for article (PubMed ID: 26983606)
1. Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice.
Schwengel K; Namsolleck P; Lucht K; Clausen BH; Lambertsen KL; Valero-Esquitino V; Thöne-Reineke C; Müller S; Widdop RE; Denton KM; Horiuchi M; Iwai M; Boato F; Dahlöf B; Hallberg A; Unger T; Steckelings UM
J Mol Med (Berl); 2016 Aug; 94(8):957-66. PubMed ID: 26983606
[TBL] [Abstract][Full Text] [Related]
2. Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury.
Fouda AY; Pillai B; Dhandapani KM; Ergul A; Fagan SC
Eur J Pharmacol; 2017 Mar; 799():128-134. PubMed ID: 28192099
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study.
Eldahshan W; Ishrat T; Pillai B; Sayed MA; Alwhaibi A; Fouda AY; Ergul A; Fagan SC
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1192-H1201. PubMed ID: 30822121
[TBL] [Abstract][Full Text] [Related]
4. AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression.
Namsolleck P; Boato F; Schwengel K; Paulis L; Matho KS; Geurts N; Thöne-Reineke C; Lucht K; Seidel K; Hallberg A; Dahlöf B; Unger T; Hendrix S; Steckelings UM
Neurobiol Dis; 2013 Mar; 51():177-91. PubMed ID: 23174180
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II type-2 receptor stimulation induces neuronal VEGF synthesis after cerebral ischemia.
Mateos L; Perez-Alvarez MJ; Wandosell F
Biochim Biophys Acta; 2016 Jul; 1862(7):1297-308. PubMed ID: 27045356
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of stroke damage by angiotensin II type 2 receptor stimulation via peroxisome proliferator-activated receptor-gamma activation.
Shan BS; Mogi M; Iwanami J; Bai HY; Kan-No H; Higaki A; Min LJ; Horiuchi M
Hypertens Res; 2018 Oct; 41(10):839-848. PubMed ID: 30089862
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of the angiotensin II AT
Bennion DM; Jones CH; Dang AN; Isenberg J; Graham JT; Lindblad L; Domenig O; Waters MF; Poglitsch M; Sumners C; Steckelings UM
Clin Sci (Lond); 2018 Mar; 132(5):581-593. PubMed ID: 29500223
[TBL] [Abstract][Full Text] [Related]
8. Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats.
McCarthy CA; Vinh A; Miller AA; Hallberg A; Alterman M; Callaway JK; Widdop RE
PLoS One; 2014; 9(4):e95762. PubMed ID: 24752645
[TBL] [Abstract][Full Text] [Related]
9. Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage.
Min LJ; Mogi M; Tsukuda K; Jing F; Ohshima K; Nakaoka H; Kan-No H; Wang XL; Chisaka T; Bai HY; Iwanami J; Horiuchi M
Am J Hypertens; 2014 Aug; 27(8):1036-44. PubMed ID: 24572705
[TBL] [Abstract][Full Text] [Related]
10. Delayed Administration of Angiotensin Receptor (AT2R) Agonist C21 Improves Survival and Preserves Sensorimotor Outcomes in Female Diabetic Rats Post-Stroke through Modulation of Microglial Activation.
Jackson-Cowan L; Eldahshan W; Dumanli S; Dong G; Jamil S; Abdul Y; Althomali W; Baban B; Fagan SC; Ergul A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572986
[TBL] [Abstract][Full Text] [Related]
11. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke.
Joseph JP; Mecca AP; Regenhardt RW; Bennion DM; Rodríguez V; Desland F; Patel NA; Pioquinto DJ; Unger T; Katovich MJ; Steckelings UM; Sumners C
Neuropharmacology; 2014 Jun; 81():134-41. PubMed ID: 24508710
[TBL] [Abstract][Full Text] [Related]
12. C21 preserves endothelial function in the thoracic aorta from DIO mice: role for AT2, Mas and B2 receptors.
González-Blázquez R; Alcalá M; Fernández-Alfonso MS; Steckelings UM; Lorenzo MP; Viana M; Boisvert WA; Unger T; Gil-Ortega M; Somoza B
Clin Sci (Lond); 2021 May; 135(9):1145-1163. PubMed ID: 33899912
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice.
Quiroga DT; Muñoz MC; Gil C; Pffeifer M; Toblli JE; Steckelings UM; Giani JF; Dominici FP
Physiol Rep; 2018 Aug; 6(16):e13824. PubMed ID: 30156060
[TBL] [Abstract][Full Text] [Related]
14. Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Jing F; Ohshima K; Wang XL; Nakaoka H; Kan-no H; Chisaka T; Bai HY; Min LJ; Horiuchi M
Eur J Pharmacol; 2014 Feb; 724():9-15. PubMed ID: 24361310
[TBL] [Abstract][Full Text] [Related]
15. Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke.
Alhusban A; Fouda AY; Bindu Pillai ; Ishrat T; Soliman S; Fagan SC
J Hypertens; 2015 Jan; 33(1):170-80. PubMed ID: 25304472
[TBL] [Abstract][Full Text] [Related]
16. Contralesional angiotensin type 2 receptor activation contributes to recovery in experimental stroke.
Fouda AY; Ahmed HA; Pillai B; Kozak A; Hardigan T; Ergul A; Fagan SC; Ishrat T
Neurochem Int; 2022 Sep; 158():105375. PubMed ID: 35688299
[TBL] [Abstract][Full Text] [Related]
17. AT
Lange C; Sommerfeld M; Namsolleck P; Kintscher U; Unger T; Kaschina E
Hypertension; 2018 Sep; 72(3):e20-e29. PubMed ID: 29987108
[TBL] [Abstract][Full Text] [Related]
18. The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Chow BS; Koulis C; Krishnaswamy P; Steckelings UM; Unger T; Cooper ME; Jandeleit-Dahm KA; Allen TJ
Diabetologia; 2016 Aug; 59(8):1778-90. PubMed ID: 27168137
[TBL] [Abstract][Full Text] [Related]
19. Chronic angiotensin AT2R activation prevents high-fat diet-induced adiposity and obesity in female mice independent of estrogen.
Nag S; Khan MA; Samuel P; Ali Q; Hussain T
Metabolism; 2015 Jul; 64(7):814-25. PubMed ID: 25869303
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin AT
Sehnert B; Valero-Esquitino V; Schett G; Unger T; Steckelings UM; Voll RE
Front Immunol; 2022; 13():921488. PubMed ID: 35874732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
